Interferon Sciences, Inc.

Douglas Testa

Mei-June Liao

Sean A Evans

Leonard F Estis

Abbas Rashidbaigi

Katalin Ferencz-Biro

Mario DiPaola

Steven R Scott

Laura C Vellucci

Manisha Padhye

Lynne D Keyes

Eva A Terpinski

This invention provides alpha interferon compositions comprising one or a mixture of selected highly antiviral interferon proteins, which compositions are characterized by increased anti-viral activity. These compositions may be used therapeutically in the treatment of viral infection, particularly retroviral or hepatitis infection or as additives to conventional antiviral agents to increase the antiviral potency thereof.

Composition containing human alpha interferon species proteins and

Two distinct alpha interferon receptor proteins have been separated and partially purified by antigen affinity chromatography and SDS-PAGE. These proteins are potentially useful as therapeutic agents. Antibodies against these proteins are potentially useful as diagnostic and therapeutic agents.

Separation of alpha interferon receptor proteins and antibodies therefor

Alpha interferon composition and method for its production from human

An interferon preparation to be administered topically is provided comprising: (a) a therapeutically effective amount of one or more interferons; (b) a vehicle base compatible with the interferon or interferons being administered; (c) an effective amount of one or more protease inhibitors for the purpose of reducing the rate of decay of the biological activity of the interferon or interferons due to proteolytic agents; and (d) an effective amount of one or more anti-microbial agents. In certain preferred embodiments of the invention, the vehicle base is prepared from a mixture of polyethylene glycols or includes hydroxyethyl cellulose as a thickening agent.

Interferon administration vehicles

A substantially non-toxic, stable, topical therapeutic composition is provided which comprises:

Topical therapeutic composition containing oxidation inhibitor system

A process and cellular system for producing soluble biological mediators, including cytokines, lymphokines, monokines and interferons, and mRNA therefor, from white blood cells is provided. The process involves treating white blood cells with a mitogenic or antigenic agent in the presence of a controlled amount of red blood cells. Increases in production of the soluble biological mediator, gamma interferon, on the order of 5 to 10 fold have been achieved by maintaining the ratio of red blood cells to white blood cells between 10 to 1 and about 50 to 1. The process is particularly useful in producing HuIFN-.gamma. with PHA-P.

Growing community of inventors

Neshanic Station, NJ, United States of America

Douglas Testa